Nascent Biotech Provides Shareholder Update on COVID-19 Therapy and Brain Cancer Trials
SAN DIEGO, April 22, 2020 (GLOBE NEWSWIRE) — Nascent Biotech, Inc., (OTCQB: NBIO) (the “Company” or “Nascent”) a leading biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer, is pleased to present its corporate update and a dynamic strategic plan, which the company has begun executing in 2020.
The Company has initiated tests to assess the possibility that its lead asset, the monoclonal antibody Pritumumab (PTB) could be used as a potential therapy against the novel coronavirus, or SARS-CoV-2, which has caused a global pandemic (COVID-19). As specifically mentioned in a 2016 article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7), cell-surface vimentin (recognized by PTB), is implicated in the entry of SARS-CoV-2, into the cells it infects. The Company has engaged independent third party consultants to conduct the tests and initial results are forthcoming.The Company’s strategic plans reveal that Nascent is also moving rapidly to human brain cancer trials with its PTB antibody. Nascent is currently finalizing the human brain cancer trial’s timeline, which includes the selection of a Contract Research Organization (CRO) to manage the clinical trials. The search for a CRO, while considered and methodical, should be completed in the coming weeks. Completion of this task is indicative of the assertive approach Nascent is taking as it implements its plans and it is a significant step forward for the Company as its management team is excited about the momentum of opening the human trials.As Nascent broadens operations, it is expanding its outreach to marketing and industry experts which will include expanding the Company’s corporate assets. Nascent is currently exploring opportunities for strategic acquisition and tactical partnerships through an array of business relationships.Sean Carrick, CEO of Nascent Biotech states, “Our strategic plan is based on the robust science of our antibody, PTB, and the strength, skill and talent of our seasoned clinical team. We look forward to Nascent meeting many key milestones in 2020 and with additional corporate outreach and development, we aspire to generate the best potential return for our shareholders.”About Nascent Biotech IncNascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.Safe Harbor:Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.Sean CarrickPresident |CEO
Nascent Biotech, Inc6330 Nancy Ridge Dr
Suite 105
San Diego CA 92121
(612) 961-5656sean.carrick@nascentbiotech.com
The Company has initiated tests to assess the possibility that its lead asset, the monoclonal antibody Pritumumab (PTB) could be used as a potential therapy against the novel coronavirus, or SARS-CoV-2, which has caused a global pandemic (COVID-19). As specifically mentioned in a 2016 article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7), cell-surface vimentin (recognized by PTB), is implicated in the entry of SARS-CoV-2, into the cells it infects. The Company has engaged independent third party consultants to conduct the tests and initial results are forthcoming.The Company’s strategic plans reveal that Nascent is also moving rapidly to human brain cancer trials with its PTB antibody. Nascent is currently finalizing the human brain cancer trial’s timeline, which includes the selection of a Contract Research Organization (CRO) to manage the clinical trials. The search for a CRO, while considered and methodical, should be completed in the coming weeks. Completion of this task is indicative of the assertive approach Nascent is taking as it implements its plans and it is a significant step forward for the Company as its management team is excited about the momentum of opening the human trials.As Nascent broadens operations, it is expanding its outreach to marketing and industry experts which will include expanding the Company’s corporate assets. Nascent is currently exploring opportunities for strategic acquisition and tactical partnerships through an array of business relationships.Sean Carrick, CEO of Nascent Biotech states, “Our strategic plan is based on the robust science of our antibody, PTB, and the strength, skill and talent of our seasoned clinical team. We look forward to Nascent meeting many key milestones in 2020 and with additional corporate outreach and development, we aspire to generate the best potential return for our shareholders.”About Nascent Biotech IncNascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.Safe Harbor:Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.Sean CarrickPresident |CEO
Nascent Biotech, Inc6330 Nancy Ridge Dr
Suite 105
San Diego CA 92121
(612) 961-5656sean.carrick@nascentbiotech.com
